Automata
Growth London
Builds modular lab-automation robotics with orchestration software to run experiments in life-sciences and diagnostics laboratories. Headquartered in London.
UK companies applying AI to scientific discovery, from biology to materials.
Growth London
Builds modular lab-automation robotics with orchestration software to run experiments in life-sciences and diagnostics laboratories. Headquartered in London.
Early-stage London
Builds a very large biological database by sampling genetic diversity from nature, then uses it to train generative foundation models for biology and drug discovery. Headquartered in London, with a laboratory in Boston.
Early-stage London
Builds an agentic AI platform over a biomedical knowledge graph to help life-sciences teams accelerate research and drug discovery. Headquartered in London.
Growth Cambridge
Builds AI models that discover and design new materials, starting with compounds that capture carbon. Headquartered in Cambridge and founded in 2024 by researchers with roots in Google DeepMind and academia.
Acquired London
Runs one of the world's leading AI research labs, behind breakthroughs including AlphaFold, AlphaGo, and the Gemini family of models. Headquartered in London and part of Google, it anchors much of the UK's AI research base.
Growth Cambridge
Uses AI to discover and repurpose drugs for rare diseases, and runs its own clinical pipeline. A University of Cambridge spinout, headquartered in Cambridge.
Growth London
Applies AI to drug discovery, using models descended from AlphaFold to predict how molecules behave and design new medicines. Headquartered in London as an Alphabet company spun out of DeepMind.
Early-stage London
Applies machine learning and lab automation to discover and optimise therapeutic antibodies, with a pipeline aimed at solid tumours. Headquartered in London.
Seed London
Uses generative AI to design proteins from scratch, aiming to make biology programmable and speed up the discovery of new therapeutics such as antibodies and enzymes. Founded in 2023 by Simon Kohl, a former co-lead of DeepMind's protein-design team and a scientist on AlphaFold2. Headquartered in London.
Early-stage London
Designs new materials using a "foundation model for atoms", targeting applications such as carbon capture, cleaner fuels, and cooling for AI data centres. Founded in 2022 by Jonathan Godwin, previously part of DeepMind's materials research. Headquartered in London.
Growth London
Builds AI simulation software for engineering and manufacturing, used in aerospace, automotive, and defence to design and test physical products faster. Headquartered in London.
Early-stage London
An AI drug-discovery company using a "lab-in-the-loop" approach that combines single-cell genomics from patient tissue, laboratory experiments, and machine learning to find new drug targets, starting with bone and immune diseases. Founded in 2019 and headquartered in London.
Early-stage Edinburgh
Uses satellite data and AI to map land cover, deforestation, and forest carbon stocks for carbon markets and supply-chain compliance. Headquartered in Edinburgh.
New PitchBook figures show UK startups raised £14.4B in the first half of 2026, with more than 70% of it going to AI and the UK taking close to 40% of all European AI funding. It is the data behind a year of big rounds, and a sign of how sharply capital is concentrating.
The UK government's AI Security Institute has stood up a dedicated Control Red Team to stress-test the safeguards that frontier labs rely on. It reported finding vulnerabilities in every version of the internal safety monitors used by Anthropic and Google DeepMind, sharpening the UK's role in frontier-AI oversight.
Cambridge company CuspAI has raised around £334M to scale its AI system for discovering new materials, in one of the largest UK AI rounds of the year. The round was led by Kleiner Perkins and NEA, with Britain's Sovereign AI Venture Fund among the backers.
Isomorphic Labs, the London drug-discovery company spun out of Google DeepMind, has raised $2.1B in its first external round, led by Thrive Capital with backing from Alphabet and GV. The money is meant to carry its AI-designed drugs toward the clinic.